(CDNA) Movement as an Input in Quant Signal Sets
The article analyzes Caredx Inc. (NASDAQ: CDNA) using AI models, highlighting a weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis emphasizes a significant risk-reward short setup for CDNA.
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
CareDx, Inc., a precision medicine company specializing in transplant patient solutions, announced its participation in the Raymond James 47th Annual Institutional Investors Conference. The conference will be held in Orlando, FL, on Tuesday, March 3, 2026. CareDx focuses on improving outcomes for transplant patients through various services, including non-invasive molecular testing, digital health technologies, and patient solutions.
Zweig DiMenna Associates LLC Buys 348,400 Shares of CareDx, Inc. $CDNA
Zweig DiMenna Associates LLC significantly increased its stake in CareDx, Inc. ($CDNA) by purchasing an additional 348,400 shares, bringing its total holdings to 575,000 shares, valued at approximately $8.36 million. Despite this institutional buying, the article also notes insider selling by CEO John Walter Hanna Jr. and a consensus "Hold" rating from analysts with an average target price of $26.67. CareDx (NASDAQ:CDNA) is a precision diagnostics company specializing in tests for transplant patients.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx announced positive clinical validation data for AlloHeme, a new blood-based monitoring test designed to predict relapses in AML and MDS patients following allogeneic hematopoietic cell transplant. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than traditional methods, supporting its commercialization beginning in 2027 as part of CareDx’s Transplant+ strategy. This advancement positions CareDx for growth in the cell therapy and hematologic oncology markets, expanding its precision medicine portfolio.
CareDx (CDNA) Projected to Post Earnings on Tuesday
CareDx (NASDAQ:CDNA) is expected to release its Q4 2025 earnings before the market opens on Tuesday, February 24th, with analysts projecting earnings of $0.24 per share and revenue of $102.76 million. The company's shares were up approximately 2.8%, trading at $19.63, and analysts have a consensus "Hold" rating with a target price of $26.67. Recent insider selling by CEO John W. Hanna Jr. and varying institutional investor activities have also been noted.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for its AlloHeme blood test, designed to predict relapses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, detecting relapses earlier than standard methods. This development strengthens CareDx's expansion into cell therapy and hematologic oncology, with commercialization planned for 2027.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for AlloHeme, a next-generation blood-based monitoring test designed to predict relapses in patients with AML and MDS following HCT. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than standard methods, supporting the company's expansion into cell therapy and hematologic oncology. CareDx plans a phased U.S. rollout for AlloHeme, with commercialization expected by 2027.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx announced positive clinical data for AlloHeme, a new blood-based test for predicting relapse in AML and MDS patients post-transplant. The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, detecting relapse earlier than traditional methods, and is expected to roll out in the U.S. with CLIA readiness in 2026. This development strengthens CareDx's "Transplant+" strategy, expanding its reach into cell therapy and hematologic oncology, and is seen as a significant growth catalyst for the company.
Does ACROBAT AlloHeme Validation Broaden CareDx’s (CDNA) Transplant+ Thesis Into Hematology-Oncology?
CareDx, Inc. (CDNA) recently announced positive clinical validation for its AlloHeme test from the ACROBAT study, showing high accuracy in detecting relapse for acute myeloid leukemia and myelodysplastic syndromes post-transplant. This expands CareDx's "Transplant+" platform beyond solid organ transplantation into hematology-oncology, potentially widening its market and revenue streams. While this is a significant step, the company's near-term investment narrative remains heavily influenced by reimbursement policies and pricing pressures on its core transplant surveillance products.
Does ACROBAT AlloHeme Validation Broaden CareDx’s (CDNA) Transplant+ Thesis Into Hematology-Oncology?
CareDx (CDNA) recently announced positive clinical validation results for AlloHeme, an AI-based blood test for predicting relapse in acute myeloid leukemia and myelodysplastic syndromes post-transplant. This expands CareDx's reach beyond solid organ transplantation into hematology-oncology, potentially diversifying its revenue streams. While this is a significant development, the article notes that reimbursement policy changes remain a critical near-term factor influencing the company's core transplant surveillance revenue.
CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data
CareDx (NASDAQ: CDNA) is expanding its "Transplant Plus" strategy into cell therapy, particularly focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) relapse monitoring after allogeneic hematopoietic cell transplantation (HCT). The company presented two-year data from its ACROBAT study for AlloHeme, a blood-based test designed to detect relapse, showing strong performance with an AUC of 0.89, sensitivity of 85%, and specificity of 92%, plus a median lead time of 41 days. CareDx projects a total addressable market of approximately $1 billion and aims for commercial launch in early 2027, with coverage decisions expected to expand by 2028.
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
CareDx announced positive clinical validation results for AlloHeme™, an AI-powered, non-invasive blood test for detecting relapse in AML and MDS patients after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study showed AlloHeme identified relapse a median of 41 days earlier than standard methods with high sensitivity and specificity. This marks a strategic expansion for CareDx into cell therapy and hematologic malignancy monitoring, with commercial launch in the U.S. anticipated in 2027.
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
CareDx, Inc. announced positive clinical validation results for AlloHeme™, an AI-powered, non-invasive, next-generation sequencing (NGS)-based test designed to detect cancer relapse earlier in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study showed AlloHeme™ identified relapse a median of 41 days before clinical detection with high sensitivity and specificity. This innovation marks a strategic expansion for CareDx beyond solid organ transplantation into cell therapy and hematologic oncology, with commercial launch anticipated in the U.S. in 2027.
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
CareDx announced the clinical validation results for AlloHeme, an AI-powered, NGS-based surveillance solution for detecting relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplant (HCT). The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, identifying relapse earlier than standard methods. This expands CareDx's precision medicine offerings into cell therapy, with commercial launch anticipated in the U.S. in 2027.
CareDx, Inc. $CDNA Stock Holdings Lessened by New York State Common Retirement Fund
New York State Common Retirement Fund significantly reduced its holding in CareDx (CDNA) by 79.7% in Q3, selling 64,175 shares and retaining 16,339 shares valued at $238,000. Additionally, CareDx CEO John Walter Hanna Jr. sold 19,280 shares, decreasing his position by 3.13%, while other institutional investors like Next Century Growth Investors LLC and Sumitomo Mitsui Trust Group Inc. increased their stakes. The stock currently has a consensus
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
CareDx, Inc. will report its financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The company will host a webcast and conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested parties can access the webcast and register for the conference call through CareDx’s Investor Relations website.
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages
CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine brokerages, with an average 1-year price target of $26.67. Insider selling by CEO John Walter Hanna Jr. for approximately $408,000 indicates a decrease in his holdings, although corporate insiders still own 4.40% of the company. Several institutional investors increased their stakes in CareDx during the fourth quarter, and the stock opened at $20.19 with a market cap of $1.04 billion.
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
CareDx, Inc. announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after market close. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Interested parties can access the webcast or register for the conference call via CareDx’s Investor Relations website.
Liquidity Mapping Around (CDNA) Price Events
Stock Traders Daily provides an AI-driven analysis of Caredx Inc. (NASDAQ: CDNA), indicating weak sentiment across all time horizons and supporting a short bias. The analysis highlights a mid-channel oscillation pattern and an exceptional 63.0:1 risk-reward short setup. It details institutional trading strategies including long, breakout, and short positions with specific entry, target, and stop-loss zones.
Can CareDx (CDNA) Turn AlloHeme’s ACROBAT Data Into a Durable Precision-Transplant Moat?
CareDx, Inc. announced that 24-month clinical validation data for its AlloHeme test will be presented at the 2026 Tandem Meetings, focusing on post-transplant relapse monitoring in AML and MDS patients. This presentation, building on interim data from 11 U.S. transplant centers, is crucial for establishing AlloHeme's clinical utility and could significantly influence CareDx's investment narrative and growth strategy. The success of AlloHeme could address concerns about the company's financial performance amidst a new management team and declining earnings expectations.
Lobbying Update: $15,000 of CAREDX lobbying was just disclosed
CAREDX (CDNA) has disclosed $15,000 in lobbying expenditures for Q4 2024, with no specific issues cited. The article also details recent insider sales activity, showing significant selling by the President and CEO and General Counsel. Furthermore, it covers institutional investor changes, analyst ratings, and price targets for CDNA stock.
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA) is set to present pivotal clinical validation data for its AlloHeme™ test at the 2026 Tandem Meetings. The AlloHeme test, an AI-powered next-generation sequencing-based peripheral blood test, is designed to detect hematologic cancer relapse earlier in patients after allogeneic hematopoietic cell transplantation. The company will also host an investor webcast on February 12, 2025, to discuss the study findings and commercial launch timeline.
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx (Nasdaq: CDNA) announced they will present pivotal clinical validation data for their AlloHeme™ test at the 2026 Tandem Meetings. This AI-powered test helps detect hematologic cancer relapse after transplantation, potentially earlier than traditional methods. The company will also host an investor webcast on February 12, 2026, to discuss the findings and commercial launch timeline.
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. announced that pivotal clinical validation data for its AlloHeme™ test will be presented at the 2026 Tandem Meetings. The ACROBAT study evaluates AlloHeme's effectiveness in detecting hematologic cancer relapse after allogeneic hematopoietic cell transplantation. CareDx will also host an investor webcast on February 12, 2025, to discuss the study findings and commercial launch timeline.
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
CareDx's CEO, John Walter Hanna Jr., sold 19,480 shares of the company stock in late January 2026, totaling approximately $412,200. These sales were pre-planned under a Rule 10b5-1 plan and represented 3.16% of his direct holdings. Despite the sale, the article suggests investors should not be concerned, as CareDx reported strong preliminary Q4 2025 results and expects continued growth in 2026, particularly for its testing services like AlloSure Kidney and AlloMap Heart.
CareDx, Inc. $CDNA Position Increased by Gagnon Securities LLC
Gagnon Securities LLC increased its stake in CareDx, Inc. (CDNA) by 11.7% in Q3 2025, bringing its total holdings to 1,729,425 shares valued at approximately $25.15 million and making CDNA its fifth-largest holding. CareDx beat Q3 expectations with $0.28 EPS and $100.06 million in revenue, a 20.7% year-over-year increase. Analysts currently have a "Hold" rating on CDNA with an average price target of $26.67.
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CareDx, Inc., a leading precision medicine company focused on transplant patient solutions, announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The event will take place in Snowbird, UT on Tuesday, February 10, 2026. CareDx specializes in non-invasive molecular testing, laboratory products, and digital health technologies to improve outcomes for transplant patients.
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CareDx, Inc. (Nasdaq: CDNA), a precision medicine company specializing in transplant patient solutions, announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference will take place in Snowbird, UT on Tuesday, February 10, 2026. CareDx focuses on non-invasive molecular testing, laboratory products, and digital health technologies to improve outcomes for transplant patients.
Is CareDx’s Upgraded 2025 Revenue Outlook Altering The Investment Case For CareDx (CDNA)?
CareDx has issued upgraded revenue guidance for Q4 and full year 2025, projecting US$108 million and US$380 million respectively, indicating strong business momentum and reinforcing investor confidence in its precision diagnostics. While this strengthens the short-term revenue growth narrative and suggests operational execution is ahead of expectations, key risks such as non-cash items, new management, and ongoing legal issues remain. Different fair value estimates from various community members reflect a wide range of expectations for CareDx's potential.
CareDx CEO Hanna sells $412,222 in shares By Investing.com
CareDx's President and CEO, John Walter Hanna Jr., sold 19,480 shares of common stock for a total of $412,222 on January 21 and 22, 2026, under a pre-arranged trading plan. Despite the insider sales, CareDx has reported strong financial performance, with significant revenue increases and strategic partnerships, although one analyst firm downgraded its stock rating. The company's HeartCare molecular testing has also shown promise in identifying high-risk heart transplant patients.
CareDx CEO Hanna sells $412,222 in shares By Investing.com
CareDx President and CEO John Walter Hanna Jr. sold 19,480 shares of common stock for a total of $412,222, as disclosed in an SEC filing. These sales, executed on January 21 and 22, 2026, were part of a pre-arranged Rule 10b5-1 trading plan. The article also notes recent positive company developments, including significant revenue increases, a new partnership with 10x Genomics, and strong Q3 2025 results, alongside a stock downgrade by Craig-Hallum.
CareDx CEO Hanna sells $412,222 in shares
CareDx CEO John Walter Hanna Jr. sold 19,480 shares of common stock for a total of $412,222 on January 21 and 22, 2026, under a pre-arranged trading plan. Despite these sales, Hanna still directly owns 597,405 shares. The company recently reported strong revenue growth for Q4 2025 and full-year 2025, announced a new research partnership, and saw its stock downgraded by Craig-Hallum to Hold.
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 19,280 Shares
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr. recently sold 19,280 shares of the company's stock for over $407,000, reducing his stake by 3.13%. Despite this insider selling, the company's shares are trading near their 50-day moving average and have a market capitalization of $1.05 billion. CareDx also reported strong quarterly earnings, beating analyst expectations, but maintains a consensus "Hold" rating with an average target price of $26.67 from analysts.
CareDx (NASDAQ:CDNA) CEO John Walter Hanna Jr Sells 10,156 Shares
CareDx CEO John Walter Hanna Jr. sold 10,156 shares of the company's stock for over $213,000 on January 15th, reducing his stake by 1.62%. This transaction follows a strong earnings report where CareDx beat analyst expectations. Analysts currently have a "Hold" consensus rating for CDNA with an average price target of $26.67.
Sumitomo Mitsui Trust Group Inc. Raises Stock Holdings in CareDx, Inc. $CDNA
Sumitomo Mitsui Trust Group Inc. significantly increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 40.7% in the third quarter of 2025, now owning 1,740,064 shares valued at approximately $25.3 million. This increase reflects broader institutional interest in the company, which recently reported strong earnings, exceeding analyst expectations with an EPS of $0.28 and revenue of $100.06 million, a 20.7% year-over-year increase. CareDx currently holds an average "Hold" rating from analysts, with a consensus target price of $26.67.
CareDx (CDNA) Is Up 19.5% After Stronger-Than-Expected 2025 Revenue Guidance - Has The Bull Case Changed?
CareDx (CDNA) saw its stock rise by 19.5% following stronger-than-expected preliminary 2025 revenue guidance, projecting approximately US$108 million for Q4 and US$380 million for the full year. This guidance, coupled with ongoing innovation, reinforces its transplant-focused business model, although potential reimbursement risks for key tests remain a concern. While the forecast suggests a 12.5% yearly revenue growth and a fair value of $23.00, investors are advised to consider various perspectives due to significant differing analyst estimates.
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of "Hold" from Analysts
Nine brokerages currently following CareDx (NASDAQ:CDNA) have issued a consensus "Hold" rating for the company, with six analysts recommending a hold and three a buy. The average 12-month price target set by these brokerages is $26.67. Despite beating recent quarterly earnings estimates with an EPS of $0.28 against an expected $0.13 and revenues increasing 20.7% year-over-year, analysts still project a negative EPS of -0.9 for the current fiscal year.
CareDx (CDNA) Valuation Check After Strong Preliminary 2025 Revenue Guidance And Transplant+ Pipeline Progress
CareDx (CDNA) is gaining attention after strong preliminary 2025 revenue guidance of $380 million and a recent collaboration, despite a 1-year share price decline. The stock's fair value is estimated at $23 per share, suggesting it is currently undervalued at $20.32, based on growth and earnings assumptions. However, this valuation depends on factors like reimbursement rates and regulatory outcomes.
Implied Volatility Surging for CareDx Stock Options
Implied volatility for CareDx (CDNA) stock options is surging, particularly for the Feb 20, 2026 $100.00 Put, indicating expectations of a significant price movement. Analysts currently rate CareDx as a Zacks Rank #2 (Buy) in the Medical Services Industry, with recent upward revisions to earnings estimates suggesting underlying strength despite the high options volatility. Options traders may view this high implied volatility as an opportunity to sell premium, betting that the stock will not move as drastically as anticipated by expiration.
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025
CareDx, Inc. (NASDAQ:CDNA) announced preliminary Q4 2025 revenue of approximately $108 million, marking a 25% year-over-year increase, and projected full-year 2025 revenue of $380 million. The company showcased strong growth across all segments, including testing services, patient and digital solutions, and product revenue, and maintained a solid financial position with robust cash reserves and share repurchase activities. Despite recent stock volatility, CareDx continues to advance its precision medicine solutions through research and strategic collaborations.
CareDx Preliminary Q4 Revenue Up 25%
CareDx, Inc. (CDNA) announced preliminary fourth quarter revenue of approximately $108 million, marking a 25% year-over-year increase. Testing services revenue grew by 23% to about $78 million, with volume up 17% to 53,000. For the full year 2025, preliminary revenue reached approximately $380 million, a 14% increase from the previous year.
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025
CareDx, Inc. (NASDAQ:CDNA) announced preliminary Q4 2025 revenue of approximately $108 million, marking a 25% year-over-year increase, and projected full-year 2025 revenue of $380 million. The company's testing services and patient/digital solutions segments showed strong growth, contributing to its financial health, which includes $200 million in cash and minimal debt. CareDx also engaged in significant share repurchases and strategic collaborations, while analysts suggest the stock may be undervalued.
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
CareDx, Inc. reported preliminary, unaudited financial results for the fourth quarter and full year 2025, expecting a 25% year-over-year revenue growth for Q4, reaching approximately $108 million. The company anticipates full-year 2025 revenue of about $380 million, a 14% increase from the previous year, driven by strong growth across all business segments. CareDx also highlighted significant share repurchases during both the quarter and the full year.
CareDx reports 25% revenue growth in Q4, expects $380 million for 2025
CareDx Inc. reported a 25% year-over-year revenue increase in Q4 2025, reaching $108 million, and projects $380 million in revenue for the full year 2025. The company also announced share repurchases of $12 million in Q4 and $88 million for the full year, while maintaining a strong balance sheet with $200 million in cash and minimal debt. Additionally, CareDx recently surpassed Q3 2025 earnings forecasts and continues to advance its research through collaborations and new study findings.
CareDx and 10x Genomics partner on transplant rejection research By Investing.com
CareDx and 10x Genomics have announced a strategic collaboration to launch ImmuneScape, a multiomics research initiative aimed at understanding transplant organ rejection. This partnership will utilize 10x Genomics' advanced platforms to investigate rejection at a cellular level, combining CareDx's clinical expertise with 10x Genomics' transcriptomics technologies. The goal of ImmuneScape is to create detailed maps of immune mechanisms underlying organ rejection and support the development of future diagnostic tools.
Assessing CareDx (CDNA) Valuation After ImmuneScape Multiomics Collaboration With 10x Genomics
CareDx (CDNA) has announced the ImmuneScape multiomics research initiative with 10x Genomics to study transplant rejection biology, drawing fresh attention to the company. Despite recent share price fluctuations, including a 27.70% return over 90 days, analysts suggest the stock is undervalued by 18.2%, with a fair value of US$23.00 against a last close of US$18.81. The valuation, however, is subject to reimbursement and regulatory outcomes.
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
CareDx, Inc. and 10x Genomics are collaborating to launch the ImmuneScape™ program, a multiomics research initiative aimed at understanding transplant organ rejection and therapeutic response. This program will utilize 10x Genomics' single cell and spatial biology platforms to generate high-resolution maps of immune mechanisms. The goal is to develop insights that can support future clinical diagnostic development and advance personalized transplant medicine.
CareDx and 10x Genomics partner on transplant rejection research By Investing.com
CareDx and 10x Genomics are collaborating on ImmuneScape, a multiomics research initiative focused on transplant organ rejection using advanced single-cell platforms. CareDx, boasting a strong financial position, aims to leverage its clinical expertise with 10x Genomics' technologies to map immune mechanisms underlying rejection and develop future clinical diagnostics. This partnership builds on CareDx's recent earnings beat and new data on its HeartCare molecular testing, despite a recent downgrade by Craig-Hallum for its stock.
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
CareDx and 10x Genomics are collaborating to launch ImmuneScape™, a multiomics research program aimed at understanding transplant rejection and drug response. This initiative will use 10x Genomics' single cell and spatial biology platforms to map immune mechanisms in organ rejection, with the goal of developing future precision diagnostics and improving patient outcomes. The project builds on CareDx's existing efforts to deepen biological understanding in transplantation and aims to characterize disease origin, trajectory, and therapeutic response.
Craig-Hallum downgrades CareDx stock rating to Hold from Buy
Craig-Hallum downgraded CareDx, Inc (NASDAQ:CDNA) from Buy to Hold due to a less compelling risk-reward profile following the stock's recovery and concerns about future revenue growth tied to regulatory decisions. Despite the downgrade, the stock is currently undervalued according to InvestingPro, which also highlights strong Q3 2025 earnings and new positive data on CareDx's HeartCare testing. The firm's outlook remains cautious, anticipating potential Q4 2025 volume dips but acknowledging possible upside if regulatory outcomes are favorable.
